BSCL2

Across TCGA pan-cancer cohorts, BSCL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BSCL2 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BSCL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BSCL2 expression acts as an unfavorable survival marker.

CCRCC, LSCC, and LUAD are the cancer types where BSCL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.817	0.969	.002	35	view →
LSCC	OS	Median	All	0.731	0.896	.005	3	view →
LUAD	DFS	Tertile	All	0.574	0.800	.046	1	view →
PDAC	DFS	Median	All	0.742	0.919	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BSCL2–CCRCC (OS)

Open the CCRCC breakdown →